Haraoka Masaki, Takamuki Mariko, Toyonaga Youichiro, Tanaka Michio, Hanazawa Kisaburo, Sakamoto Yoshiro, Horie Shigeo
Nihon Hinyokika Gakkai Zasshi. 2014 Oct;105(4):212-7. doi: 10.5980/jpnjurol.105.212.
A 62-year-old man were referred our hospital complaining of high prostate specific antigen (PSA) value (32.4 ng/ml) in May 2010. Two sets of biopsies preformed previously at another hospital had not detected any cancers in the prostate. In our hospital, prostate biopsies were performed in July 2010 and February 2011, but cancer was not detected in either occasion. In March 2011, his PSA increased up to 126.7 ng/ml, CT scan showed the swelling of left supraclavicular and para-aortic lymph nodes. Biopsy of the supraclavicular lymph node was performed. Pathology revealed poorly differentiated adenocarcinoma with positive immunohistochemistry for PSA, which was suggestive of metastatic prostate cancer. After 1 year of treatment with androgen deprivation therapy, the patient developed castration resistant prostate cancer and have undergone chemotherapy with docetaxel.
一名62岁男性于2010年5月因前列腺特异性抗原（PSA）值高（32.4 ng/ml）转诊至我院。此前在另一家医院进行的两组活检均未在前列腺中检测到任何癌症。在我院，于2010年7月和2011年2月进行了前列腺活检，但两次均未检测到癌症。2011年3月，他的PSA升至126.7 ng/ml，CT扫描显示左锁骨上和主动脉旁淋巴结肿大。对锁骨上淋巴结进行了活检。病理显示为低分化腺癌，PSA免疫组化阳性，提示为转移性前列腺癌。经过1年的雄激素剥夺治疗后，该患者发展为去势抵抗性前列腺癌，并接受了多西他赛化疗。
